Intranasal immunization with a proteosome-adjuvanted SARS-CoV-2 spike protein-based vaccine is immunogenic and efficacious in mice and hamsters.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
13 06 2022
Historique:
received: 02 03 2022
accepted: 27 05 2022
entrez: 13 6 2022
pubmed: 14 6 2022
medline: 16 6 2022
Statut: epublish

Résumé

With the persistence of the SARS-CoV-2 pandemic and the emergence of novel variants, the development of novel vaccine formulations with enhanced immunogenicity profiles could help reduce disease burden in the future. Intranasally delivered vaccines offer a new modality to prevent SARS-CoV-2 infections through the induction of protective immune responses at the mucosal surface where viral entry occurs. Herein, we evaluated a novel protein subunit vaccine formulation containing a resistin-trimerized prefusion Spike antigen (SmT1v3) and a proteosome-based mucosal adjuvant (BDX301) formulated to enable intranasal immunization. In mice, the formulation induced robust antigen-specific IgG and IgA titers, in the blood and lungs, respectively. In addition, the formulations were highly efficacious in a hamster challenge model, reducing viral load and body weight loss. In both models, the serum antibodies had strong neutralizing activity, preventing the cellular binding of the viral Spike protein based on the ancestral reference strain, the Beta (B.1.351) and Delta (B.1.617.2) variants of concern. As such, this intranasal vaccine formulation warrants further development as a novel SARS-CoV-2 vaccine.

Identifiants

pubmed: 35697917
doi: 10.1038/s41598-022-13819-5
pii: 10.1038/s41598-022-13819-5
pmc: PMC9191540
doi:

Substances chimiques

Adjuvants, Immunologic 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
COVID-19 Vaccines 0
Spike Glycoprotein, Coronavirus 0
spike protein, SARS-CoV-2 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

9772

Informations de copyright

© 2022. Crown.

Références

Infect Immun. 1993 Jun;61(6):2390-5
pubmed: 8500877
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Sci Transl Med. 2021 Aug 18;13(607):
pubmed: 34315826
Clin Exp Vaccine Res. 2012 Jul;1(1):50-63
pubmed: 23596577
Nat Commun. 2021 Feb 15;12(1):1018
pubmed: 33589636
mBio. 2021 Jun 29;12(3):e0069621
pubmed: 34060334
J Biotechnol. 2018 Sep 10;281:39-47
pubmed: 29886030
Lancet Microbe. 2022 Jan;3(1):e52-e61
pubmed: 34806056
Allergy. 2022 Jan;77(1):258-270
pubmed: 34519053
Int Immunopharmacol. 2020 Sep;86:106717
pubmed: 32585611
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Science. 2021 Sep 17;373(6561):1372-1377
pubmed: 34385356
Vaccine. 2007 Aug 21;25(34):6334-40
pubmed: 17640780
Science. 2020 Mar 13;367(6483):1260-1263
pubmed: 32075877
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Expert Rev Vaccines. 2010 Apr;9(4):431-40
pubmed: 20370552
Vaccine. 2021 May 6;39(19):2605-2607
pubmed: 33846043
Lancet. 2021 Dec 11;398(10317):2173-2184
pubmed: 34774196
Science. 2021 Jul 23;373(6553):397-399
pubmed: 34437109
Nat Med. 2005 Apr;11(4 Suppl):S45-53
pubmed: 15812489
Vaccine. 2003 Sep 8;21(25-26):3706-12
pubmed: 12922101
Nature. 2021 Jun;594(7862):253-258
pubmed: 33873199
Cell. 2020 Jul 23;182(2):429-446.e14
pubmed: 32526206
Cell. 2020 May 28;181(5):1004-1015.e15
pubmed: 32375025
Vaccines (Basel). 2021 Nov 10;9(11):
pubmed: 34835238
Sci Rep. 2021 Nov 8;11(1):21849
pubmed: 34750472
Expert Rev Vaccines. 2012 Mar;11(3):367-79
pubmed: 22380827
Vaccine. 2017 Jun 5;35(25):3318-3325
pubmed: 28499553
Expert Rev Vaccines. 2011 Mar;10(3):365-75
pubmed: 21434804
Vaccines (Basel). 2021 Aug 09;9(8):
pubmed: 34452006
Proc Natl Acad Sci U S A. 2020 Jul 14;117(28):16587-16595
pubmed: 32571934
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Gastroenterology. 2004 Jul;127(1):300-9
pubmed: 15236195
N Engl J Med. 2021 Feb 18;384(7):643-649
pubmed: 33378605
N Engl J Med. 2021 Jun 3;384(22):2092-2101
pubmed: 33835769
Sci Immunol. 2020 Oct 8;5(52):
pubmed: 33033173
PLoS One. 2016 Dec 22;11(12):e0163089
pubmed: 28005959
PLoS Pathog. 2021 Dec 2;17(12):e1010022
pubmed: 34855916
Infect Immun. 1995 Jun;63(6):2382-6
pubmed: 7768627
Methods Mol Biol. 2022;2412:179-231
pubmed: 34918246
Epidemiol Infect. 2021 Nov 04;149:e237
pubmed: 34732275

Auteurs

Felicity C Stark (FC)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Bassel Akache (B)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada. Bassel.akache@nrc-cnrc.gc.ca.

Lise Deschatelets (L)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Anh Tran (A)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Matthew Stuible (M)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Yves Durocher (Y)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Michael J McCluskie (MJ)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Gerard Agbayani (G)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Renu Dudani (R)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Blair A Harrison (BA)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Tyler M Renner (TM)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Shawn R Makinen (SR)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Jegarubee Bavananthasivam (J)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Diana Duque (D)

National Research Council Canada, Human Health Therapeutics, 1200 Montreal Road, Ottawa, ON, K1A 0R6, Canada.

Martin Gagne (M)

Biodextris Inc., 525 boul. Cartier West, Laval, QC, H7V 3S8, Canada.

Joseph Zimmermann (J)

Inspirevax Inc., 46 rue de Saint-Tropez, Kirkland, QC, H9J 2K6, Canada.

C David Zarley (CD)

Oragenics, Inc., 13700 Progress Blvd, Alachua, FL, 32608, USA.
CDZarley LLC., 133 Butternut Dr, Pottstown, PA, 19464, USA.

Terrence R Cochrane (TR)

Oragenics, Inc., 13700 Progress Blvd, Alachua, FL, 32608, USA.
BrevisRefero Corporation, 295 Alliance Road Suite 1B/C, Milton, ON, L9T 2X7, Canada.

Martin Handfield (M)

Oragenics, Inc., 13700 Progress Blvd, Alachua, FL, 32608, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH